X-Biotix Therapeutics launched today with technology from Harvard Medical School that the company said will aim to address the threat of antibiotic resistance.
According to the multi-year collaboration and license agreement, the team plans to identify antibiotic scaffolds that target multi-drug-resistant Gram-negative pathogens.
X-Biotix spun out of the privately-held biotech X-Chem, which develops novel small molecule therapeutics using its DNA-encoding technology platform, DEX. X-Biotix plans to use the DEX platform to discover and develop chemical scaffolds that target Gram-negative pathogens.
Get the full story at our sister site, Drug Delivery Business News.
The post X-Biotix to address antibiotic resistance with chemical scaffolds appeared first on MassDevice.
from MassDevice http://ift.tt/2shTEyA
Cap comentari:
Publica un comentari a l'entrada